156.90k followers • 18 symbols Watchlist by Yahoo Finance
Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis
Curated by Yahoo Finance
Global spending on legal cannabis worldwide will hit $57 billion in a decade, according to Arcview Market Research and BDS Analytics. Driven by the legalization of recreational and medical cannabis and the increasing demand for both, legal cannabis revenue in the U.S. is projected to hit $23.4 billion by 2022. Yahoo Finance is now tracking the major players in the cannabis industry.How do we pick these stocks?
This is a curated list, powered by Yahoo Finance’s algorithm and intelligence from our millions of users as well as the Yahoo Finance editorial team. The list covers companies in horticulture, pharmaceutical research and ancillary businesses. We will continue to add names as corporations invest and pivot into the space.How are these weighted?
The stocks on this watchlist are weighted equally at the time they were added.
To learn what every company on this list is doing that involves cannabis, read this story.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|ABBV||AbbVie Inc.||131.98||-1.05||-0.79%||4:02 pm GMT-5||7.58M||6.57M||233.32B|
|BUD||Anheuser-Busch InBev SA/NV||65.13||-0.46||-0.70%||4:00 pm GMT-5||1.43M||1.87M||114.26B|
|MO||Altria Group, Inc.||50.32||-0.01||-0.02%||4:03 pm GMT-5||8.80M||8.68M||92.44B|
|TAP||Molson Coors Beverage Company||48.62||-0.75||-1.52%||4:00 pm GMT-5||1.65M||1.73M||10.57B|
|SMG||The Scotts Miracle-Gro Company||149.23||-5.01||-3.25%||4:00 pm GMT-5||327.80k||414.82k||8.21B|
|WEED.TO||Canopy Growth Corporation||9.16||-0.30||-3.17%||4:00 pm GMT-5||2.66M||2.39M||3.61B|
|CGC||Canopy Growth Corporation||7.29||-0.27||-3.57%||4:00 pm GMT-5||7.22M||7.68M||2.88B|
|TLRY||Tilray Brands, Inc.||5.79||-0.13||-2.20%||4:00 pm GMT-5||25.14M||24.09M||2.70B|
|CRON||Cronos Group Inc.||3.43||-0.14||-3.92%||4:00 pm GMT-5||2.67M||3.38M||1.28B|
|ACB||Aurora Cannabis Inc.||4.46||-0.29||-6.11%||4:00 pm GMT-5||6.45M||5.58M||886.26M|
|NBEV||NewAge, Inc.||0.7299||-0.01||-0.98%||4:00 pm GMT-5||1.12M||1.55M||107.16M|
|CRBP||Corbus Pharmaceuticals Holdings, Inc.||0.467||-0.04||-8.57%||4:00 pm GMT-5||1.15M||1.08M||58.48M|
|TGODF||The Green Organic Dutchman Holdings Ltd.||0.07715||-0.00||-5.91%||3:57 pm GMT-5||926.55k||854.96k||42.92M|
|CANN||General Cannabis Corp||0.3202||-0.01||-2.02%||3:31 pm GMT-5||157.94k||153.12k||27.15M|
|MJ||ETFMG Alternative Harvest ETF||9.77||-0.35||-3.46%||4:00 pm GMT-5||1.67M||1.44M||-|
Treasury yields are rising, and the Federal Reserve is expected to raise interest rates multiple times in 2022. In the case of AbbVie (NYSE: ABBV), look no further. AbbVie is a global prescription drug developer, manufacturer, and distributor that was spun off from parent company Abbott Labs back in 2013.
The legal cannabis industry in Canada must continue to consolidate to make it an attractive space for investors.
In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022. Which clinical results are you especially looking forward to seeing? Brian Orelli: Arena (NASDAQ: ARNA), the ticker there is A-R-N-A, it expects data from a phase 3 study of etrasimod in patients with ulcerative colitis.